Stocksigma LogoStocksigma Logo

Natco Pharma Increases Investment in eGenesis to US$16.70 Million

Natco Pharma has increased its planned investment in US-based biotechnology firm eGenesis, Inc. from US$14.00 million to US$16.70 million via convertible

Natco Pharma Increases Investment in eGenesis to US$16.70 Million

Natco Pharma Ltd 路 Press Release 路 28 Sept 2026, 8:28 pm

Natco Pharma Increases Investment in eGenesis to US$16.70 Million Natco Pharma has increased its planned investment in US-based biotechnology firm eGenesis, Inc. from US$14.00 million to US$16.70 million via convertible promissory notes carrying an 8% annual interest rate. The transaction comprises US$13.70 million via Natco Pharma (Canada) Inc. and US$3.00 million via Natco Pharma USA LLC, with completion targeted by 31st Oct'26. Following an earlier US$8.00 million investment in 2024, Natco's total commitment will rise to US$24.70 million, backing eGenesis's multiplex gene-editing platform for cross-species organ transplantation.

Original exchange filing (PDF)

More announcements from Natco Pharma Ltd

All Natco Pharma Ltd announcements